Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash from Discontinued Operations (2021 - 2022)

Historic Cash from Discontinued Operations for Theravance Biopharma (TBPH) over the last 2 years, with Q4 2022 value amounting to -$179.0 million.

  • Theravance Biopharma's Cash from Discontinued Operations fell 645539.77% to -$179.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$184.6 million, marking a year-over-year change of. This contributed to the annual value of -$184.6 million for FY2022, which is 76112.4% down from last year.
  • Latest data reveals that Theravance Biopharma reported Cash from Discontinued Operations of -$179.0 million as of Q4 2022, which was down 645539.77% from -$5.2 million recorded in Q3 2022.
  • In the past 5 years, Theravance Biopharma's Cash from Discontinued Operations ranged from a high of $2.8 million in Q4 2021 and a low of -$179.0 million during Q4 2022